After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?

Moderna's stock has surged nearly 90% in 2026, driven by positive FDA news about its flu vaccine mRNA-1010 in June. However, the rally appears unjustified as the vaccine is unlikely to generate significant revenue ($1B by 2028) and the company faces fundamental challenges including $3.4B in operating losses over the trailing 12 months, declining revenue, and dependence on COVID vaccine sales. With a $20B+ market cap and limited compelling growth catalysts beyond the experimental cancer vaccine mRNA-4157, the stock appears overvalued for its risk profile.

07/27/2026, 4:02 PM • The Motley Fool

IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?

IXJ and RSPH are two healthcare ETFs with different strategies: IXJ uses cap-weighted global exposure with larger pharmaceutical companies, offering higher dividends (1.47%) and lower volatility (beta 0.52), while RSPH employs equal-weighting of S&P 500 healthcare stocks, providing stronger 1-year returns (21.01% vs 18.29%) but higher risk (beta 0.81). The choice depends on investor goals—IXJ suits conservative/income-focused investors, while RSPH appeals to growth-oriented investors willing to accept volatility.

07/21/2026, 1:32 PM • The Motley Fool

Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?

Moderna stock has surged 109% in 2026 as the biotech company successfully transitions from a coronavirus vaccine player to a multi-product company. With cost reductions of 26%, three approved products, and promising late-stage candidates in oncology and rare diseases, analysts view it as increasingly investable. Though the stock has pulled back 24% from its July peak, it remains a buy for long-term investors, though cautious investors may wait for further progress on pipeline candidates.

07/20/2026, 6:10 PM • The Motley Fool

Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes

ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

07/17/2026, 6:48 AM • GlobeNewswire

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its dominant cystic fibrosis portfolio into rare endocrine disorders. The deal provides access to Palsonify for acromegaly and a pipeline asset for congenital adrenal hyperplasia, potentially adding $5 billion in peak annual revenue. While the price is fair and strategically sound, results aren't expected until 2029, making it a long-term growth play for the biotech company.

07/10/2026, 4:05 AM • The Motley Fool

Moderna Stock Is Soaring. Is It Too Late to Buy?

Moderna's stock has more than doubled this year as the company transitions from a COVID-19 vaccine maker to a diversified biotech firm. With multiple late-stage vaccine programs (flu, norovirus, combination vaccines) and cancer therapies in development, the company is preparing for major product launches in 2027-2028. Strong financials including $7.5 billion in cash and improving revenue support long-term growth potential, though recent gains reflect high expectations and clinical risks remain.

07/07/2026, 5:15 AM • The Motley Fool

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More

Three biotech companies—Moderna, Revolution Medicines, and Axsome Therapeutics—significantly outperformed the S&P 500 in the first half of 2026 with double- and triple-digit gains. While Moderna faces expected pullback despite flu vaccine approval prospects, and Revolution Medicines shows modest upside, Wall Street expects Axsome to climb another 13% due to recent drug approvals and strong pipeline progress.

07/06/2026, 6:10 PM • The Motley Fool

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?

The Fidelity MSCI Health Care Index ETF (FHLC) offers broad healthcare sector exposure with lower costs (0.08% expense ratio), higher dividend yield (1.3%), and lower volatility, making it suitable for conservative investors. The State Street SPDR S&P Biotech ETF (XBI) focuses on biotechnology with higher growth potential (89.3% 1-year return) but carries significantly higher risk (54% maximum drawdown) and costs (0.35% expense ratio), appealing to aggressive investors.

07/05/2026, 9:15 AM • The Motley Fool

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

Biogen announced a $1 billion acquisition of RayThera, a company with anti-inflammatory assets targeting immune-mediated conditions. This strategic move strengthens Biogen's immunology portfolio following its earlier acquisition of Apellis Pharmaceuticals. The company is successfully transitioning from its declining MS drug business to growth areas like Alzheimer's and rare diseases, with early signs of business stabilization and revenue growth.

07/04/2026, 4:02 AM • The Motley Fool

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

07/03/2026, 11:14 AM • The Motley Fool

Is Moderna Stock a No-Brainer Buy After a Key FDA Win?

Moderna received FDA advisory committee approval for its mRNA-based flu vaccine (mRNA-1010) for patients 50+, with potential FDA approval by August 5. The company also announced plans to develop an in vivo CAR-T candidate. However, despite a 150% surge over the past year and bullish sentiment, much of the comeback potential is already priced into the stock. With a $26.7 billion market cap while unprofitable, and the flu vaccine market estimated at only $9.5 billion, investors may want to wait for hype to fade before buying.

06/30/2026, 2:15 PM • The Motley Fool

Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

06/30/2026, 12:26 AM • The Motley Fool

Should You Buy Moderna Before Aug. 5?

Moderna's investigational flu vaccine candidate (mRNA-1010) received unanimous FDA advisory panel approval, with a regulatory decision expected by August 5. The stock has surged over 100% this year as the company reaches a key transition point with multiple product launches planned for 2027-2028. However, the analyst suggests waiting for a post-approval dip to buy, as much of the good news may already be priced in.

06/22/2026, 6:10 PM • The Motley Fool

Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?

Moderna's stock has surged over 100% this year as the company diversifies beyond COVID-19 vaccines using its mRNA platform. Key catalysts include FDA approval of mFlusiva (flu vaccine) expected August 5, 2026, and the European Commission's approval of mCOMBRIX (flu-COVID combination vaccine). The company's most transformative opportunity lies in cancer vaccines, with phase 3 data for mRNA-4157 expected later in 2026. Despite 260% revenue growth in Q1 2026, Moderna remains unprofitable but has $7.5 billion in cash and targets company-wide breakeven by 2028.

06/20/2026, 7:30 AM • The Motley Fool

These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead

Three stocks—Moderna, Krystal Biotech, and AMD—have significantly outperformed the S&P 500 this year and are positioned for continued growth. Moderna is advancing toward approvals for its influenza and norovirus vaccines plus cancer vaccine candidates. Krystal Biotech's gene therapy Vyjuvek for rare skin disease is generating strong earnings with expansion opportunities. AMD is capitalizing on AI growth through its server CPU leadership and gaining market share from Intel.

06/18/2026, 1:30 AM • The Motley Fool